secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001171843-22-007153
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences Q3 net loss $20.3M; Phase 3 Alzheimer's trial enrollment tops 650
--------------------------------------------------------------------------------

- Net loss $20.3M ($0.51/share) vs $9.6M loss in Q3 2021; R&D expenses rose to $18.5M.
- Cash and equivalents $174.7M with no debt; FY 2022 cash burn guidance $80-90M.
- Over 650 patients now enrolled in simufilam Phase 3 studies, up from 150 six months ago.
- Open-label study results expected year-end 2022; Cognition Maintenance Study results Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/f8k_110422.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer